SCD

TIF Releases New Scientific Bulletin To Highlight Research On Haemoglobin Disorders
Actualités

TIF Releases New Scientific Bulletin To Highlight Research On Haemoglobin Disorders

A key objective of the Thalassaemia International Federation is to inform and update regularly the global haemoglobinopathies family, both patients and physicians, on the progress and new developments that arise…
UK & Wales: NICE Recommends First Treatment In Two Decades For Sickle Cell Disease
Actualités

UK & Wales: NICE Recommends First Treatment In Two Decades For Sickle Cell Disease

For the first time in 20 years, a new therapy for sickle cell disease is to be made available on the UK National Health Service (NHS). Crizanlizumab (Adakveo) by Novartis…
Global Blood Submits US Application For Expanded Use Of SCD Drug, Oxbryta, In Patients Aged 4-11 Years
Actualités

Global Blood Submits US Application For Expanded Use Of SCD Drug, Oxbryta, In Patients Aged 4-11 Years

Children with sickle cell disease (SCD) as young as age 4 could be prescribed Oxbryta (Voxelotor) if the U.S. Food and Drug Administration (FDA) approves a supplemental new drug application (sNDA) submitted by…
Adakveo (Crizanlizumab)
Clinical Trial Updates (SCD)

Adakveo (Crizanlizumab)

Update: 30 June 2021 No update available   Update: 08 January 2021 Data presented at ASH2020 confirm that no new safety signals were identified in the enrolled SCD population treated…
Oxbryta (Voxelotor)
Clinical Trial Updates (SCD)

Oxbryta (Voxelotor)

Update: 30 June 2021 A new analysis of data from 45 children with SCD, aged 4 to 11 years, enrolled in the open-label Phase 2a HOPE-KIDS 1 Study (GBT440-007) showed…
Clinical Trials Update: The June 2021 Edition
Actualités

Clinical Trials Update: The June 2021 Edition

TIF provides you with comprehensive and up-to-date information on developing drugs and therapies for thalassaemia and sickle cell disease (SCD) currently in clinical trials. Our most recent June 2021 update…
TIF Is Actively Participating In The 26th EHA Annual Congress
Actualités

TIF Is Actively Participating In The 26th EHA Annual Congress

TIF is excited to be participating in the 26th EHA Annual Congress, held this year virtually on 09 – 17 June 2021. Ms Lily Cannon, TIF Operations Manager, attended a…
Bluebirdbio Announces The Lifting Of FDA Clinical Hold for Sickle Cell Disease And β-Thalassaemia Studies
Actualités

Bluebirdbio Announces The Lifting Of FDA Clinical Hold for Sickle Cell Disease And β-Thalassaemia Studies

bluebird bio, Inc. today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin…
Oxbryta Increased Haemoglobin And Reduced Haemolysis in Adults and Adolescents With SCD
Actualités

Oxbryta Increased Haemoglobin And Reduced Haemolysis in Adults and Adolescents With SCD

Global Blood Therapeutics, Inc. announced The Lancet Haematology has published the complete analysis of 72-week data from the Phase 3 HOPE Study of Oxbryta® (voxelotor) tablets in patients with sickle cell disease…
TIF Presents Its Newly Launched SCD Educational Course for Healthcare Professionals On 9 April
Actualités

TIF Presents Its Newly Launched SCD Educational Course for Healthcare Professionals On 9 April

TIF is delighted to announce the organisation of a Virtual Presentation Event of the ‘TIF Sickle Cell Disease Educational Course for Healthcare Professionals’ – an online course providing comprehensive information…
Bouton retour en haut de la page